drugset / Trial / NCT07346495
A Study of Remternetug (LY3372993) in Healthy Chinese Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period.
Timeline
- Start
- 2026-01-31
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remternetug | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.